High-potency ligands for DREADD imaging and activation in rodents and monkeys

[1]  D. Kätzel,et al.  Pharmacokinetic and pharmacodynamic actions of clozapine-N-oxide, clozapine, and compound 21 in DREADD-based chemogenetics in mice , 2019, Scientific Reports.

[2]  H. Gendelman,et al.  Neurotheranostics as personalized medicines. , 2019, Advanced drug delivery reviews.

[3]  Reid H. J. Olsen,et al.  DREADD Agonist 21 Is an Effective Agonist for Muscarinic-Based DREADDs in Vitro and in Vivo , 2018, ACS pharmacology & translational science.

[4]  Philip G. F. Browning,et al.  Behavioral Effect of Chemogenetic Inhibition Is Directly Related to Receptor Transduction Levels in Rhesus Monkeys , 2018, The Journal of Neuroscience.

[5]  Brandon K. Harvey,et al.  Chemogenetics revealed: DREADD occupancy and activation via converted clozapine , 2017, Science.

[6]  Thomas Wichmann,et al.  Metabolism and Distribution of Clozapine-N-oxide: Implications for Nonhuman Primate Chemogenetics. , 2017, ACS chemical neuroscience.

[7]  Yasuyuki Kimura,et al.  PET imaging-guided chemogenetic silencing reveals a critical role of primate rostromedial caudate in reward evaluation , 2016, Nature Communications.

[8]  B. Richmond,et al.  Multimodal Imaging for DREADD-Expressing Neurons in Living Brain and Their Application to Implantation of iPSC-Derived Neural Progenitors , 2016, The Journal of Neuroscience.

[9]  Damien A. Fair,et al.  The Rhesus Monkey Connectome Predicts Disrupted Functional Networks Resulting from Pharmacogenetic Inactivation of the Amygdala , 2016, Neuron.

[10]  Richard C Saunders,et al.  Chemogenetic disconnection of monkey orbitofrontal and rhinal cortex reversibly disrupts reward value , 2015, Nature Neuroscience.

[11]  Hyunah Choo,et al.  The First Structure–Activity Relationship Studies for Designer Receptors Exclusively Activated by Designer Drugs , 2015, ACS chemical neuroscience.

[12]  M. Michaelides,et al.  DREAMM: A Biobehavioral Imaging Methodology for Dynamic In Vivo Whole-Brain Mapping of Cell Type-Specific Functional Networks , 2015, Neuropsychopharmacology.

[13]  B. Roth,et al.  Chemogenetic tools to interrogate brain functions. , 2014, Annual review of neuroscience.

[14]  N. Volkow,et al.  Whole-brain circuit dissection in free-moving animals reveals cell-specific mesocorticolimbic networks. , 2013, The Journal of clinical investigation.

[15]  D. Kleinfeld,et al.  ReaChR: A red-shifted variant of channelrhodopsin enables deep transcranial optogenetic excitation , 2013, Nature Neuroscience.

[16]  K. Mackie,et al.  Expression of G protein-coupled receptors and related proteins in HEK293, AtT20, BV2, and N18 cell lines as revealed by microarray analysis , 2011, BMC Genomics.

[17]  B. Roth,et al.  Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand , 2007, Proceedings of the National Academy of Sciences.

[18]  R. Friesner,et al.  Novel procedure for modeling ligand/receptor induced fit effects. , 2006, Journal of medicinal chemistry.

[19]  H. Kung,et al.  Noninvasive quantification of dopamine D2 receptors with iodine-123-IBF SPECT. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  G. Stöcklin,et al.  Synthesis of n.c.a. carbon-11 labelled clozapine and its major metabolite clozapine-N-oxide and comparison of their biodistribution in mice. , 1994, Nuclear medicine and biology.

[21]  S. Zoghbi,et al.  Evaluation of ultrafiltration for the free-fraction determination of single photon emission computed tomography (SPECT) radiotracers: beta-CIT, IBF, and iomazenil. , 1994, Journal of pharmaceutical sciences.